June 2020 - Reithera

By ef

Strategies to enhance the induction of high magnitude T cell responses through vaccination are urgently needed. Major histocompatibility complex (MHC) class II–associated invariant chain (Ii) [...]

ArcticZymes has entered into an agreement with ReiThera to supply its SAN product for ReiThera’s COVID-19 vaccine candidate

Tromsø, 02 July, 2020: ArcticZymes AS (OSE:AZT), a subsidiary of ArcticZymes Technologies ASA, announces that it has entered into a supply agreement with vaccine specialist ReiThera Srl (Rome, [...]

SGS JOINS FORCES WITH LEADING BIOTECH REITHERA TO FAST-TRACK ITS SINGLE-DOSE COVID-19 VACCINE

SGS has joined forces with leading European biotech company ReiThera to fast-track the development and production of a single-dose COVID-19 vaccine. Italian Biotech ReiThera selected SGS to [...]

MHC class II invariant chain–adjuvanted viral vectored vaccines enhances T cell responses in humans

ArcticZymes has entered into an agreement with ReiThera to supply its SAN product for ReiThera’s COVID-19 vaccine candidate

SGS JOINS FORCES WITH LEADING BIOTECH REITHERA TO FAST-TRACK ITS SINGLE-DOSE COVID-19 VACCINE